BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,  announced its financial results for the first quarter of fiscal year 2025, reporting a strong revenue of $5.2 billion, a 9.8% increase compared to the same period last year. In conjunction with this performance update, BD also unveiled its intent to separate its Biosciences and Diagnostic Solutions businesses into an independent, publicly traded company, reinforcing its commitment to driving focused innovation and long-term growth.

First-Quarter Fiscal 2025 Financial Performance BD’s robust revenue growth was driven by strong demand across its Medical, Life Sciences, and Interventional segments. Key highlights from the quarter include:

• Total revenue of $5.2 billion, marking a 9.8% year-over-year increase.

• Strong performance in Biosciences, propelled by increasing adoption of research tools and advanced diagnostic solutions.

• Improved operating margins reflecting BD’s ongoing efforts in operational efficiency and strategic investments.

• Continued expansion of BD’s global footprint, with notable growth in emerging markets.

“BD’s strong financial results in the first quarter reflect our ability to deliver innovative solutions that meet the evolving needs of healthcare providers and researchers worldwide,” said Tom Polen, Chairman, CEO, and President of BD. “Our continued investment in R&D, operational excellence, and strategic partnerships positions BD for sustained long-term success.”

Strategic Business Separation to Unlock Value and Enhance Focus As part of its commitment to enhancing focus and accelerating growth, BD has announced its intent to separate its Biosciences and Diagnostic Solutions businesses into a new, independent publicly traded entity. This planned separation is expected to unlock significant value for shareholders and enable both BD and the newly formed company to concentrate on their respective core strengths.

The independent company, once established, will focus on advancing innovations in biosciences and diagnostics, with an emphasis on accelerating breakthroughs in research, laboratory automation, and precision diagnostics. The separation is expected to provide both organizations with:

• Greater operational focus and flexibility to drive targeted investment in innovation.

• Enhanced ability to pursue strategic partnerships and market expansion.

• Stronger alignment with evolving industry trends and customer needs.

“The decision to separate our Biosciences and Diagnostic Solutions businesses is a pivotal step in BD’s strategy to create two distinct, innovation-driven companies,” added Polen. “This separation will allow BD to focus on its core MedTech business while enabling the new entity to maximize its growth potential and deliver advanced solutions to researchers and healthcare providers.”

BD anticipates completing the separation by the end of fiscal year 2025, subject to customary conditions, regulatory approvals, and final Board approval. Further details regarding the transaction structure and leadership appointments for the new company will be provided in the coming months.